Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports

Sylvie Négrier 1,2*, Guillaume Moriceau 2, Valéry Attignon 3, Véronique Haddad 4, Daniel Pissaloux 4, Nicole Guerin 5 and Christian Carrie 6

Abstract

Background: Renal cell carcinoma represents 3–5% of adult malignant tumors. Metastases are found in 30–40% of patients and brain metastases occurred in more than 10% of them. Despite significant progress in medical treatment, patients with brain metastases still have a limited survival. Cabozantinib, a tyrosine kinase inhibitor directed against vascular endothelial growth factor receptors, was recently registered for the treatment of metastatic renal cell carcinoma. Almost no data are, however, available on patients with brain metastases.

Case presentation: Case 1 is a 51-year-old man of North African origin; Case 2 is a 55-year-old European man. Case 1 and Case 2 had metastases of renal carcinoma at initial diagnosis and were treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors. Case 1 had clear cell renal carcinoma and underwent nephrectomy; he then received several lines of tyrosine kinase inhibitor directed against vascular endothelial growth factor receptors and the mTor complex. During the second treatment a brain metastasis was diagnosed and treated with radiosurgery with rapid efficacy. Two years later he received nivolumab, an antibody directed against the programmed death-1 and programmed death-ligand 1 complex, but disease progression was observed with the reappearance of the brain metastasis together with neurologic symptoms. Cabozantinib was administered and induced a rapid clinical improvement as well as tumor regression in all sites including his brain. Sequencing of his tumor evidenced a mutation of the MET gene. Case 2 had a papillary renal carcinoma with brain metastases at time of diagnosis. After radiation of the brain tumors, a vascular endothelial growth factor receptor tyrosine kinase inhibitor was administered for 3 years. The disease was under control in all sites except in his brain; several new brain metastases requiring new radiation treatments developed. The disease finally progressed at all metastatic sites including his brain and he had several neurological symptoms. Cabozantinib was administered and rapidly induced a clinical improvement; a further computed tomography scan and brain magnetic resonance imaging showed significant tumor regressions. No MET gene mutation or amplification was observed in the tumor analysis.

Conclusions: These case reports indicate that cabozantinib was able, first, to reach brain tumors and second, to induce significant regressions in renal carcinoma brain metastases that were resistant to radiation as well as to previous systemic vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Keywords: Renal cell carcinoma, Brain metastases, Cabozantinib, Tyrosine kinase inhibitor, VEGFr inhibitors

* Correspondence: sylvie.negrier@lyon.unicancer.fr
1Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France
2Department of Medical Oncology, Centre Léon Bérard, Lyon, France
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Renal carcinoma represents 3–5% of the incidence of adult malign tumors. The more common histologic subtype is clear cell carcinoma and it accounts for more than 75% of cases; several minor subtypes are diagnosed among the remaining 25% of cases. Papillary carcinoma, type I or II, is the most frequent of these minor subtypes and accounts for 10% of all cases. Surgery with partial or radical nephrectomies cures most patients and disease-specific survival at 5 years is between 70 and 80% [1, 2]. Metastases often occur in the 2 to 5 years following surgery but are uncommon at initial diagnosis. Metastases are frequently located in lungs and lymph nodes, but also in bones and liver; brain metastases are uncommon at initial work up; he patients die after a survival period varying from 1 to 3–4 years depending on the prognosis factors [1]. Due to specific gene alterations, the vascular endothelial growth factor (VEGF) pathway is a major driver of clear cell renal carcinoma development, which is the most frequent histologic subtype, and, as a consequence, VEGF or VEGF receptor (VEGFr) inhibitors are key in the treatment of these patients [1]. Other genes, especially MET, involved in the carcinogenesis of a number of tumors, were also found to be determinants for tumor progression and resistance to treatments. MET was first identified as a major driver for the development of papillary renal carcinoma, but was also shown to be involved in resistant clear cell carcinomas [6–8]. Different MET or dual MET and VEGF-targeted therapies were recently investigated through clinical trials [9, 10]. One of the most recently registered targeted therapies for the treatment of mRCC, cabozantinib, is a tyrosine kinase inhibitor (TKI) directed against VEGFr, but also against other different genes: c-Met, RET, and AXL [11].

We describe two cases of mRCC who developed resistant brain metastases despite several systemic treatments as well as stereotaxic radiation. Cabozantinib induced significant tumor reductions including the life-threatening brain metastases.

Case presentation
Case 1 is a 51-year-old man of North African origin with a history of hypertension who had been diagnosed as having a right kidney tumor associated with one bulky pleural metastasis and some smaller metastatic lesions of the lung; Case 1 is summarized in Fig. 1. No bone or brain metastases were observed at initial work up; he was classified in the poor risk group according to the International Metastatic RCC Database Consortium (IMDC) [12]. A radical nephrectomy was performed in July 2012. A pathological report indicated a renal cell carcinoma (RCC) of 16 cm with a clear cell component and some degree of a more aggressive cellular component, giving a Fuhrman grade of 4, pT3a pN0 M1 according to the Union for International Cancer Control (UICC) classification. Sunitinib, 50 mg/day, then reduced to 37.5 mg due to side effects, was administered during 6 months. Because of the painful progression of the pleural metastasis in the upper part of his left lung, radiation therapy was delivered to this tumor. Systemic treatment was further modified for the approved second-line treatment everolimus. This latter treatment induced a significant tumor response in most metastatic sites for 15 months before re-progression. In March 2014, our patient complained of persistent headaches and brain magnetic resonance imaging (MRI) identified a single right frontal metastasis. Stereotactic radiotherapy was performed and a treatment with axitinib, a second-line TKI directed against VEGFr, was started. Axitinib induced significant tumor shrinkage in the pleural and lung metastases; the brain metastasis was much improved because a brain MRI was considered almost normal. Axitinib was maintained for 18 months, but had to be completed because of a severe episode of angina pectoris. A coronary stent that required dual anti-platelet therapy for 6 months was indicated. Due to an increased hemorrhagic risk with this treatment together with a VEGFr inhibitor, axitinib was not resumed; nivolumab, a programmed death-1 (PD1) directed antibody recently approved for mRCC treatment, was administered as part of a compassionate program. Our patient was admitted with seizures and vertigo 4 months after immunotherapy initiation. A brain MRI evidenced the enlargement, with some hemorrhagic traits, of the previously treated metastasis. Further to therapeutic control of his neurological symptoms, a thoracic and abdominal computed tomography (CT) scan showed the progression of the disease at all metastatic sites. He then entered a genetic profiling experimental program (NCT 01774409) and sequencing of the primary tumor was performed. Due to the long duration of this analysis, cabozantinib that had been recently made available was administered after our patient gave consent. All neurological symptoms disappeared and his performance status (PS) score improved to 0 after 2 weeks of treatment with cabozantinib. A brain MRI and thoracoabdominal CT scan at 8 weeks indicated a significant shrinkage of the metastatic lesions including the brain metastasis (Fig. 2).

Treatment was rather well tolerated but had to be reduced to 40 mg per day instead of 60 mg, due to fatigue, stomatitis, and loss of weight. Cabozantinib is ongoing with a reduced dose of 40 mg/day with a maintained efficacy over
8 months. Meanwhile, results of the tumor sequencing indicated the expression of mutation of the MET gene.

Case 2 is a 55-year-old European man with a history of hypertension who presented to the emergency room with seizures in December 2013; Case 2 is summarized in Fig. 3. A brain CT scan and further MRI showed three tumors surrounded by cerebral edema. A left kidney tumor and two lung nodules were identified by CT scan and, finally, clinical examination found some hypervascularized lesions of his scalp. The cutaneous tumors were surgically removed and the pathological report identified metastases of a type 2 papillary renal tumor. This patient was classified in the favorable risk group according to the International Metastatic RCC Database Consortium (IMDC) [12]. Brain metastases were all treated by stereotaxic radiation. Pazopanib another TKI directed to VEGFr was initiated at 800 mg/day. This treatment induced a partial response in lung metastases and in the primary renal tumor; the three brain metastases were also reduced. The disease remained stable for 2.5 years under pazopanib, except in his brain. In fact, two new brain metastases appeared 12 months later and three others after 24 months. Stereotaxic radiation was performed on each new brain tumor and pazopanib at 800 mg per day was resumed. Some neurological symptoms appeared with several transient episodes of aphasia together with some degree of mental confusion, 4 months after the last radiation treatment. Pazopanib treatment was completed and brain MRI indicated a radionecrosis with surrounding cerebral edema in one of the recently irradiated brain metastases. Two months after pazopanib completion, a CT scan showed significant progression in
all other metastatic sites including previously irradiated brain metastases. Cabozantinib was started after our patient gave consent. Neurological symptoms rapidly resolved and a brain MRI at 2.5 months evidenced tumor regression of the different brain metastases (Fig. 4). Cabozantinib was ongoing for 6 months but had to be reduced to 40 mg/day due to grade 3 diarrhea. Sequencing was performed on the metastatic tumor sample but no MET mutation was identified and no MET gene amplification was observed.

Fig. 2 Brain magnetic resonance imaging of Case 1. a July 2016, b December 2016, c May 2017 4 months under cabozantinib

Fig. 3 Case 2 timeline. CT computed tomography, MRI magnetic resonance imaging
Discussion
To the best of our knowledge, this is one of the two first reports of efficacy of cabozantinib in brain metastases of RCC. Cabozantinib is a TKI directed against VEGFr as well as MET, RET and AXL gene expression [11, 13]. Cabozantinib was approved by both the US Food and Drug Administration and the European Medicines Agency in 2016 for the treatment of mRCC after failure of previous treatments with angiogenesis inhibitors. In fact, cabozantinib was shown to improve progression-free survival (PFS) and overall survival over everolimus in patients with advanced or mRCC [11, 14]. More recently, PFS with cabozantinib was found superior to sunitinib in patients with non-pretreated mRCC in a randomized phase 2 trial [15]. None of these trials enrolled patients with active brain metastases; as a consequence, the potential efficacy of cabozantinib is unknown at this specific tumor site. After a review of the literature, we found a case report on the regression of brain metastases in a patient with RCC and one non-small cell lung carcinoma (NSCLC) under cabozantinib [16, 17]. These cases demonstrated the potential activity of cabozantinib on the brain, which is an unfavorable site in all patients with metastases. In addition, our two cases demonstrate the potential efficacy of cabozantinib in radioresistant brain metastases of RCC. Some retrospective analyses reported some tumor regression in brain metastases under other VEGFr inhibitors, mostly sunitinib, but efficacy appeared limited when investigated in a specific trial [3, 18, 19]. A hypothesis of a correlation between the effect of cabozantinib on resistant brain metastases and MET inhibition can be raised.

In our first case, cMet was found mutated and the second case has a papillary carcinoma which is known to commonly have MET gene alterations, although no mutation in this gene was found in the tumor of this patient [6, 20]. Notably, a MET mutation was present in the case of NSCLC with brain metastases successfully treated by cabozantinib [17]. Recently, some results indicated more frequent MET gene mutations or overexpression in brain metastases of patients with mRCC compared to primary tumor or other metastatic sites [21, 22].

Conclusions
These case reports indicate that orally administered cabozantinib is able to reach brain tumors and to induce regressions in metastases from RCC that were resistant to radiation and previous angiogenic TKI. A prospective trial with cabozantinib in patients with mRCC and brain metastases is required, as well as further investigations on the role of the MET gene in these patients.

Abbreviations
CT: Computed tomography; IMDC: International Metastatic RCC Database Consortium; mRCC: Metastatic renal cell carcinoma; MRI: Magnetic resonance imaging; NSCLC: Non-small cell lung carcinoma; PD1: Programmed death-1; PFS: Progression-free survival; PS: Performance status; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor; UICC: Union for International Cancer Control; VEGF: Vascular endothelial growth factor; VEGFr: Vascular endothelial growth factor receptor

Acknowledgements
Acknowledgements to Stephanie Labourier for her help in typewriting the article.

Funding
No specific funding was obtained.
Availability of data and materials
All data, images, and results are available on demand to the corresponding author including the signed consent forms.

Authors’ contributions
SN, GM, VA, VH, DP, NG, and CC participated in the patients’ care, provided data and discussed the different elements brought into the case reports, critically reviewed the reports, and agreed to the submission of the final version. In addition, SN wrote the different versions of the report and made a literature search of other cases and finally selected the reference list. SN, GM, VA, VH, DP, and NG read and approved the final manuscript.

Ethics approval and consent to participate
The CARE guidelines were thoroughly followed to present each case. Each patient was informed of the case report publication project and further accepted it in signing.

Consent for publication
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consents is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consents is available for review by the Editor-in-Chief of this journal.

Competing interests
Sylvie Negrier received honoraria from Pfizer, Novartis, BMS, Ipsen, Eusa pharma. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Univ Lyon, Université Claude Bernard Lyon 1, Lyon, France. 2Department of Medical Oncology, Centre Léon Bérard, Lyon, France. 3Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France. 4Department of Bio-Pathology, Centre Léon Bérard, Lyon, France. 5Department of Radiology, Centre Léon Bérard, Lyon, France. 6Department of Radiation Therapy, Centre Léon Bérard, Lyon, France.

Received: 5 January 2018 Accepted: 8 October 2018
Published online: 25 November 2018

References
1. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376:354–66.
2. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.
3. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501–9.
4. Cagnéry DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Rogan DA, Alexander BM, Aizer AA. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy. A population-based study. Neuro-Oncology. 2017;19:1511–21. https://doi.org/10.1093/neuonc/nox077.
5. Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni GS, Hamilton RJ, Fleshner NE. Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series. Urol Oncol. 2017;35:661.e7–661.e14. https://doi.org/10.1016/j.urolonc.2017.06.060.
6. Linehan, et al Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016;374(12):135–45.
7. Shojaiie F, Lee JH, Simmons BH, Wong A, Esparza CO, Plummer PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10900–100.
8. Gibney GT, Astz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–9.
9. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TT, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MM, Adams LM, Ottesen LH, Laubacher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Battaro DP, Linehan WM, Srivivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.
10. Choueiri TK, Choueiri TJ, Pimmack E, Arkenau HT, Jonash E, DyC H, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albigez L, Pal SK. Biomarker-based Phase II Trial of Sunitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2013;31(26):2993–3001. 201310.1200/JCO.2013.72.2967
11. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JS, Peltola K, Roth BJ, Bjaamason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borman-Hagay A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ, METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814–23.
12. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eglit BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a, multicenter study. J Clin Oncol. 2009;27(34):5794–9.
13. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Benztfen C, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.
14. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label phase 3 trial. Lancet Oncol. 2016;17(11):1917–27.
15. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olenczi T, Piccus J, Small EJ, Dakhil S, George DJ, Morris MJ. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017;35(6):591–7.
16. Ciccossere C, Iacovelli R, Mosillo C, Tortora G. Exceptional response to cabozantinib of rapidly evolving brain metastases of renal cell carcinoma: a case report and review of the literature. Clin Genitourin Cancer. 2018; https://doi.org/10.1016/j.clgc.2018.06.005.
17. Klempner SJ, Borghiea A, Hakimian B, Ali SM, Ou Si. Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases. J Thorac Oncol. 2017;12(1):152–6.
18. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Porrata P, Menon M, Montorsi F, Karakiewicz PI. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):497–80.
19. Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F, Tosi D, Oudard S, Blanc E, Ferlay C, Négrier S, French Group on Renal Cancer. A phase II trial of sunitinib in patients with renal cell carcinoma and untreated brain metastases. Clin Genitourin Cancer. 2014;12(1):50–4.
20. Albigez L, Guegan J, Le Formal A, Verkame V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allyon Y, Crear C, Couvé S, Gad P, Fatard JJ, Escudier B. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 2014;20(3):341–21.
21. Schiefer AI, Mesteri I, Berghoff AS, Hafei T, Schmidinger M, Preusser M, Bimer P. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal carcinoma reveals cMet as a negative prognostic factor. Histopathology. 2015;67(8):799–805.
22. Denosi L, et al. Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2017; 35(15_suppl):4569.